Our team of experts brings you cancer-related news, features, and survivor stories.
Published on: January 24, 2020
The US Food and Drug Administration (FDA) has approved Tazverik (tazemetostat) to treat adults and children 16 and older with epithelioid sarcoma, a rare cancer which accounts for less than 1% of all soft tissue sarcomas.
If this was helpful, donate to help fund patient support services, research, and cancer content updates.